RNA-enabled gene editing model
RNA-enabled gene editing programs use nucleic acid payloads to express or deliver gene-editing machinery in a transient and controllable manner. These programs may involve CRISPR-Cas systems, base editors, prime editors, recombinases, transposases, or other engineered editing platforms, with payload formats including editor-encoding mRNA, circRNA, guide RNA, sgRNA, or RNA-based multi-component combinations.
Key CMC challenges
For RNA-enabled editing, the key CMC challenge is not only producing high-quality RNA components, but also integrating payload design, expression duration, guide RNA integrity, delivery efficiency, safety profile, and scalable drug product manufacturing. Editor RNA and guide RNA often have different quality attributes, stability profiles, impurity risks, and formulation requirements, which should be considered early in development.
CATUG integrated support
CATUG supports RNA-enabled gene editing programs through plasmid and IVT template preparation, mRNA and circRNA drug substance manufacturing, gRNA/sgRNA-related workflows, LNP/tLNP drug product formulation, analytical development, GMP manufacturing, fill-finish where applicable, and CMC documentation. Our RNA platform supports multiple payload formats and modification strategies to help clients evaluate expression performance, manufacturability, and development feasibility.
Process safety and impurity control
Process safety and impurity control are central to gene editing CMC. CATUG has established process development capabilities for dsRNA reduction, residual impurity control, RNA integrity optimization, purification strategy development, and stage-appropriate analytical control. These capabilities help reduce process-related risks and support more controlled workflows from early feasibility to IND-enabling and clinical-stage programs.
LNP and tLNP delivery support
On the delivery side, CATUG supports LNP/tLNP formulation screening, lipid composition optimization, encapsulation development, particle size and PDI control, RNA loading and encapsulation efficiency optimization, and scale-up for RNA and guide RNA payloads. CATUG also has experience with MaxMix™ LNP processes designed to improve manufacturing scalability, process robustness, and transition from early formulation screening to GMP-oriented production.
Why CATUG for RNA-enabled gene editing
Depending on the program stage, clients can engage CATUG for selected modules such as editor RNA, guide RNA, LNP formulation, analytics, or GMP manufacturing, or for an integrated RNA editing CMC workflow. CATUG helps innovators translate RNA-enabled editing concepts into developable, scalable, and quality-controlled therapeutic programs.
Multi-payload gene editing model
Many gene editing programs require more than a single RNA payload. In addition to editor RNA and guide RNA, certain editing strategies may involve donor DNA, ssDNA, dsDNA, plasmid donor templates, linearized DNA templates, or DNA/RNA combination payloads to support repair, insertion, replacement, or more complex genome engineering mechanisms. These multi-payload workflows create additional CMC complexity in material quality, compatibility, analytics, and delivery strategy.
Key development questions
For donor-template or DNA/RNA combination programs, key development questions include donor template design, DNA quality and integrity, guide RNA compatibility, editor expression window, payload ratio, formulation feasibility, residual impurity control, and analytical methods for each critical component. The CMC strategy must consider not only each payload individually, but also how multiple payloads interact during formulation, delivery, release testing, stability, and scale-up.
CATUG integrated support
CATUG has experience supporting diverse gene editing payload formats, including plasmid DNA, linearized DNA templates, ssDNA, RNA, mRNA, circRNA, gRNA/sgRNA, and DNA/RNA combination workflows. Our integrated platform allows clients to access plasmid, RNA, guide RNA, donor-template-related support, LNP/tLNP formulation, analytical development, GMP-oriented manufacturing, and CMC documentation under one coordinated workflow.
Donor-template and compatibility support
For programs involving DNA or ssDNA donor templates, CATUG can support stage-appropriate template preparation, quality control, impurity assessment, documentation, and compatibility evaluation with RNA or LNP-based workflows where applicable. For multi-component editing programs, we help clients assess manufacturability, formulation constraints, analytical requirements, and development risks before moving toward IND-enabling execution.
Delivery-system development
CATUG’s delivery-system experience includes multiple lipid chemistries, innovative lipid designs, diverse carrier formats, particle attribute control, and internal lipid IP development to support next-generation gene editing delivery strategies. Where targeted or complex delivery is required, CATUG supports project-specific feasibility assessment rather than one-size-fits-all platform claims.
Why CATUG for complex gene editing
CATUG helps clients build a practical CMC path for complex gene editing programs by integrating payload preparation, delivery development, analytics, GMP manufacturing, and regulatory-oriented documentation from early feasibility through IND-enabling and clinical-stage development.
CATUG supports RNA-enabled gene editing programs through integrated plasmid / IVT template preparation, editor mRNA or circRNA manufacturing, gRNA / sgRNA workflows, mRNA + sgRNA co-encapsulation, LNP / tLNP formulation, analytical development, MaxMix™ scale-up, GMP-oriented manufacturing, and CMC documentation.
For many RNA-enabled gene editing programs, editor mRNA plus sgRNA / gRNA remains the most common payload route. CATUG supports payload quality, co-encapsulation, particle engineering, analytical characterization, and scalable LNP / tLNP process development.
RNA-enabled gene editing typically requires coordinated development of editor RNA and guide RNA, with formulation strategies designed for co-encapsulation, controlled particle attributes, efficient delivery, and stage-appropriate manufacturability.
For selected emerging editing strategies, donor DNA, ssDNA, dsDNA, plasmid donor templates, linearized templates, or DNA/RNA combinations may be evaluated as program-specific exploratory payload routes.
Gene editing programs require RNA quality, co-encapsulation control, particle engineering, flexible process routes, and scalable manufacturing.
RNA process development for dsRNA reduction and residual impurity control.
mRNA + sgRNA co-encapsulation and multi-payload analytical support.
Particle size tuning for application-specific delivery needs.
Flexible formulation routes with scalable MaxMix™ process translation.
Innovative lipid process development and scale-up experience.
Supports editor-encoding mRNA and circRNA payload strategies for transient expression, manufacturability evaluation, RNA integrity control, dsRNA reduction, impurity control, and stage-appropriate RNA DS manufacturing.
Supports guide RNA / sgRNA-related workflows and mRNA + sgRNA co-encapsulation development, including payload ratio evaluation, encapsulation efficiency, particle attributes, and multi-payload analytical strategy.
Supports plasmid construction, supercoiled plasmid manufacturing, linearized IVT template preparation, and documentation for editor RNA, guide RNA, and selected donor-template-related workflows.
Supports formulation development using microfluidic systems such as PNI or CATUG proprietary MaxMix™ routes. MaxMix™ provides strong advantages for scalable process translation and cost-effective GMP-oriented production.
Supports particle size tuning, low PDI, high encapsulation efficiency, RNA loading optimization, lipid composition development, and application-specific LNP attribute control for gene editing delivery needs.
Supports innovative lipid process development, scale-up, residual impurity control, RNA and DNA quality testing, particle attributes, release testing, stability, CoA, batch records, and CMC source documentation.
Gene editing programs require early alignment of editing mechanism, editor RNA format, guide RNA design, mRNA + sgRNA co-encapsulation strategy, LNP formulation route, particle attribute control, analytical development, and GMP manufacturability.
Built for CRISPR-Cas, base editing, prime editing, and other RNA-enabled editing systems where editor RNA, sgRNA / gRNA, co-encapsulation, particle engineering, and scalable LNP manufacturing must be evaluated together.